These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22063066)

  • 1. Role of the blood service in cellular therapy.
    Rebulla P; Giordano R
    Biologicals; 2012 May; 40(3):218-21. PubMed ID: 22063066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Education of laboratory technicians at graduate school contributes to development of advanced medical sciences and therapeutics].
    Maekawa T
    Rinsho Byori; 2004 May; 52(5):430-4. PubMed ID: 15206130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Establishment of institutional GMP cell processing is mandatory for the development of novel advanced cell and gene therapy].
    Maekawa T
    Rinsho Ketsueki; 2004 Jan; 45(1):32-8. PubMed ID: 14999932
    [No Abstract]   [Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational research on advanced therapies.
    Belardelli F; Rizza P; Moretti F; Carella C; Galli MC; Migliaccio G
    Ann Ist Super Sanita; 2011; 47(1):72-8. PubMed ID: 21430343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs.
    Abou-El-Enein M; Römhild A; Kaiser D; Beier C; Bauer G; Volk HD; Reinke P
    Cytotherapy; 2013 Mar; 15(3):362-83. PubMed ID: 23579061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of advanced therapy medicinal products in Europe and the role of academia.
    Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
    Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell standardization: purity and potency.
    Wagner BJ
    Regen Med; 2012 Nov; 7(6 Suppl):89-92. PubMed ID: 23210818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. French and European regulations for tissue and cell therapy.
    Caunday O; Bultel S; Decot V; Bensoussan D; Stoltz JF
    Biomed Mater Eng; 2012; 22(4):255-9. PubMed ID: 22785369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current regulatory issues in cell and tissue therapy.
    Burger SR
    Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood transfusion in Europe: basic principles for initial and continuous training in transfusion medicine: an approach to an European harmonisation.
    Mueller MM; Seifried E
    Transfus Clin Biol; 2006 Nov; 13(5):282-5; quiz 286-9. PubMed ID: 17196864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiovascular regenerative medicine at the crossroads. Clinical trials of cellular therapy must now be based on reliable experimental data from animals with characteristics similar to human's].
    Nadal-Ginard B; Torella D; Ellison G
    Rev Esp Cardiol; 2006 Nov; 59(11):1175-89. PubMed ID: 17144992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges of running a GMP facility for regenerative medicine in a public hospital.
    Viganò M; Giordano R; Lazzari L
    Regen Med; 2017 Oct; 12(7):803-813. PubMed ID: 29115906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rise of cellular therapy.
    Choate J; Snyder EL
    Transfus Apher Sci; 2011 Aug; 45(1):91-7. PubMed ID: 21742555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing.
    Silva DN; Chrobok M; Ahlén G; Blomberg P; Sällberg M; Pasetto A
    Immunooncol Technol; 2022 Dec; 16():100099. PubMed ID: 36389443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products.
    Hourd P; Chandra A; Alvey D; Ginty P; McCall M; Ratcliffe E; Rayment E; Williams DJ
    Regen Med; 2014; 9(6):799-815. PubMed ID: 25431916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature.
    Damerval M; Fagnoni-Legat C; Louvrier A; Fischer S; Limat S; Clairet AL; Nerich V; Madelaine I; Kroemer M
    Front Med (Lausanne); 2021; 8():713047. PubMed ID: 34926483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the Istituto Superiore di Sanità as the competent authority for Phase I trials in the translation of advanced therapies.
    Popoli P; Cometa MF; Fabi F; Meneguz A
    Ann Ist Super Sanita; 2011; 47(1):79-82. PubMed ID: 21430344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular cardiac regenerative therapy in which patients?
    Chachques JC
    Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):911-9. PubMed ID: 19673669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Traceability of labile blood products in Morocco: experience of the Ibn-Sina hospital of Rabat between 1999 and 2010].
    Ouadghiri S; Atouf O; Brick C; Benseffaj N; Essakalli M
    Transfus Clin Biol; 2012 Feb; 19(1):1-4. PubMed ID: 22269085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.